ChinaDrugStatus

Insulin icodec / Semaglutide

依柯胰岛素司美格鲁肽
Brand: IcoSema·Endocrinology / Metabolic·Last verified 2026-11-20

Fixed-ratio once-weekly basal insulin and GLP-1 agonist combination newly added to the 2026 NRDL Negotiated List (#18) for adult T2D.

China Approval (NMPA)

Pending Verification

Reimbursement catalog entries for this drug are verified from NHSA official PDFs. Individual NMPA registration certificate numbers (国药准字) and approval dates are queued for incremental verification.

Verify directly on NMPA Portal ↗

National Reimbursement

Announced · Effective Jan 1, 2027
2026 Edition Entry
Negotiated #18 · Class B
Agreement Period
2027-01-01 to 2028-12-31
Payment Standard
* Confidential (marked with asterisk in NHSA PDF)
2026 Payment Scope
Restricted to adults with Type 2 Diabetes mellitus inadequately controlled on basal insulin or a GLP-1 receptor agonist.
限接受基础胰岛素或胰高糖素样肽1(GLP-1)受体激动剂治疗后血糖控制不佳的成人2型糖尿病患者。

Commercial Insurance List

Not Listed

Not listed in the 2025 or 2026 NHSA Commercial Health Insurance Innovative Drug List.

Approved Products, Dosage Forms & Approval Numbers

0 verified NMPA records
Individual NMPA approval numbers (国药准字) and dosage strength rows have not yet been manually backfilled for this drug in our launch sample. Check the NMPA Drug Database Portal ↗ or request priority backfill.

Change Timeline

  1. (2027-01-01)Basic NRDL· Catalog published: Nov 14, 2026

    2026 NRDL · Added to Negotiated List

    Newly added to 2026 NRDL Negotiated List (#18, Class B, *) for adult T2D inadequately controlled on basal insulin or GLP-1 receptor agonist.

    Chinese original: 新增纳入2026版谈判药品第18项(乙类,支付标准*),限基础胰岛素或GLP-1受体激动剂控制不佳的成人2型糖尿病患者。

    NHSA · PDF p.118Verified 2026-11-20

Verified Names & Aliases

Every English INN, Chinese generic name, brand name, and R&D code is recorded with its source.

依柯胰岛素司美格鲁肽注射液dosage name(NHSA)
IcoSemacode(WHO)

Primary Sources for This Record